Author

Aurélie Hatton

Centre National de la Recherche ScientifiqueORCID 0000-0002-8985-9625Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Genetics· 1 Molecular Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Isabelle Sermet‐GaudelusiD· 2 shared Alexandre HinzpeteriD· 1 shared Anita GoleciD· 1 shared Batsheva KeremiD· 1 shared Camille Rullaud· 1 shared Chen LeibsoniD· 1 shared Claudia SerotiD· 1 shared David CornuiD· 1 shared

Activity by Year

2021-2024 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMolecular Biology

Isabelle Sermet‐GaudelusORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

TLN468 changes the pattern of tRNA used to readthrough premature termination codons in CFTR

Sabrina Karri, David Cornu, Claudia Serot, Lynda Biri, Aurélie Hatton, Elise Dréanot, Camille Rullaud, Iwona Maria Pranke, Isabelle Sermet‐Gaudelus, Alexandre Hinzpeter, Laure Bidou, Olivier Namy

This study shows TLN468 promotes specific amino acid incorporation at CFTR PTCs, leading to functional CFTR variants, while gentamicin does not significantly alter amino acid proportions.

Journal of Cystic Fibrosis · Aug 3, 2024Peer-reviewedMolecular Biology

Antisense oligonucleotide-based drug development for Cystic Fibrosis patients carrying the 3849+10kb C-to-T splicing mutation

Yifat S. Oren, Michal Irony‐Tur Sinai, Anita Golec, Ofra Barchad-Avitzur, Venkateshwar Mutyam, Li Yao, Jeong Shin Hong, Efrat Ozeri-Galai, Aurélie Hatton, Chen Leibson, Liran Carmel, Joel M. Reiter, Eric J. Sorscher, Steve Donald Wilton, Eitan Kerem, , Batsheva Kerem

This study develops an antisense oligonucleotide (ASO) therapy for CF patients with the 3849+10kb C-to-T splicing mutation, showing restoration of CFTR function in patient-derived cells.

Journal of Cystic Fibrosis · Jul 2, 2021Peer-reviewedGenetics